Search

Your search keyword '"Yeung, Tsz-Lun"' showing total 159 results
Start Over Author "Yeung, Tsz-Lun"
159 results on '"Yeung, Tsz-Lun"'

5. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth

Author

Yang, Lifeng, Achreja, Abhinav, Yeung, Tsz-Lun, Mangala, Lingegowda S., Jiang, Dahai, Han, Cecil, Baddour, Joelle, Marini, Juan C., Ni, Joseph, Nakahara, Ryuichi, Wahlig, Stephen, Chiba, Lisa, Kim, Sun Hye, Morse, Joshua, Pradeep, Sunila, Nagaraja, Archana Sidalaghatta, Haemmerle, Monika, Kyunghee, Noh, Derichsweiler, Mathew, Plackemeier, Thomas, Mercado-Uribe, Imelda, Lopez-Berestein, Gabriel, Moss, Tyler, Ram, Prahlad T., Liu, Jinsong, Lu, Xiongbin, Mok, Samuel C., Sood, Anil K., and Nagrath, Deepak

Published
2016
Full Text
View/download PDF

6. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance

Author

Leung, Cecilia S., Yeung, Tsz-Lun, Yip, Kay-Pong, Wong, Kwong-Kwok, Ho, Samuel Y., Mangala, Lingegowda S., Sood, Anil K., Lopez-Berestein, Gabriel, Sheng, Jianting, Wong, Stephen T.C., Birrer, Michael J., and Mok, Samuel C.

Subjects
Cell adhesion molecules -- Properties, Drug resistance -- Genetic aspects, Ovarian cancer -- Drug therapy, Fibroblasts -- Genetic aspects, Health care industry
Abstract

The molecular mechanism by which cancer-associated fibroblasts (CAFs) confer chemoresistance In ovarian cancer Is poorly understood. The purpose of the present study was to evaluate the roles of CAFs in modulating tumor vasculature, chemoresistance, and disease progression. Here, we found that CAFs upregulated the lipoma-preferred partner (LPP) gene in microvascular endothelial cells (MECs) and that LPP expression levels in intratumoral MECs correlated with survival and chemoresistance in patients with ovarian cancer. Mechanistically, LPP increased focal adhesion and stress fiber formation to promote endothelial cell motility and permeability. siRNA- mediated LPP silencing in ovarian tumor-bearing mice improved paclitaxel delivery to cancer cells by decreasing intratumoral microvessel leakiness. Further studies showed that CAFs regulate endothelial LPP via a calcium-dependent signaling pathway involving microfibrillar-associated protein 5 (MFAP5), focal adhesion kinase (FAK), ERK, and LPP. Thus, our findings suggest that targeting endothelial LPP enhances the efficacy of chemotherapy in ovarian cancer. Our data highlight the importance of CAF-endothelial cell crosstalk signaling in cancer chemoresistance and demonstrate the improved efficacy of using LPP-targeting siRNA in combination with cytotoxic drugs., Introduction High-grade serous ovarian cancer (HGSC) is the most common histological subtype of ovarian cancer and accounts for most ovarian cancer-related deaths. Most HGSCs are diagnosed at a late stage, [...]

Published
2018
Full Text
View/download PDF

7. Supplementary Figure 4 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 3 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 1 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table 2 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table 3 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 2 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

14. Data from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure Legend from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

27. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses

Author

Lan, Yan, primary, Yeung, Tsz-Lun, additional, Huang, Hui, additional, Wegener, Ansgar A, additional, Saha, Somdutta, additional, Toister-Achituv, Mira, additional, Jenkins, Molly H, additional, Chiu, Li-Ya, additional, Lazorchak, Adam, additional, Tarcic, Ohad, additional, Wang, Hong, additional, Qi, Jin, additional, Locke, George, additional, Kalimi, Doron, additional, Qin, Guozhong, additional, Marelli, Bo, additional, Yu, Huakui, additional, Gross, Alec W, additional, Derner, Melissa G, additional, Soloviev, Maria, additional, Botte, Mathieu, additional, Sircar, Aroop, additional, Ma, Hong, additional, Sood, Vanita D, additional, Zhang, Dong, additional, Jiang, Feng, additional, and Lo, Kin-Ming, additional

Published
2022
Full Text
View/download PDF

31. Ryanodine Receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes

Author

Zhang, Li, primary, Huang, Chunxian, additional, Yeung, Tsz-Lun, additional, Ferri-Borgogno, Sammy, additional, AuYeung, Chilam, additional, Lawson, Barrett C., additional, Kwan, Suet-Ying, additional, Thomas, Vienna, additional, Lu, Karen H., additional, Yip, Kay-Pong, additional, Sham, James S.K., additional, and Mok, Samuel, additional

Published
2021
Full Text
View/download PDF

32. Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion

Author

Lan, Yan, primary, Moustafa, Mahmoud, additional, Knoll, Maximilian, additional, Xu, Chunxiao, additional, Furkel, Jennifer, additional, Lazorchak, Adam, additional, Yeung, Tsz-Lun, additional, Hasheminasab, Sayed-Mohammad, additional, Jenkins, Molly H., additional, Meister, Sarah, additional, Yu, Huakui, additional, Schlegel, Julian, additional, Marelli, Bo, additional, Tang, Zili, additional, Qin, Guozhong, additional, Klein, Carmen, additional, Qi, Jin, additional, Zhou, Cheng, additional, Locke, George, additional, Krunic, Damir, additional, Derner, Melissa G., additional, Schwager, Christian, additional, Fontana, Rachel E., additional, Kriegsmann, Katharina, additional, Jiang, Feng, additional, Rein, Katrin, additional, Kriegsmann, Mark, additional, Debus, Juergen, additional, Lo, Kin-Ming, additional, and Abdollahi, Amir, additional

Published
2021
Full Text
View/download PDF

34. Ryanodine receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes.

Author

Zhang, Li, Au-Yeung, Chi-Lam, Huang, Chunxian, Yeung, Tsz-Lun, Ferri-Borgogno, Sammy, Lawson, Barrett C., Kwan, Suet-Ying, Yin, Zheng, Wong, Stephen T., Thomas, Vienna, Lu, Karen H., Yip, Kay-Pong, Sham, James S. K., and Mok, Samuel C.

Subjects
RYANODINE receptors, UTERINE cancer, PROTEIN microarrays, OVERALL survival, PHENOTYPES, REPERFUSION injury
Abstract

Background: Uterine serous cancer (USC) is the most common non-endometrioid subtype of uterine cancer, and is also the most aggressive. Most patients will die of progressively chemotherapy-resistant disease, and the development of new therapies that can target USC remains a major unmet clinical need. This study sought to determine the molecular mechanism by which a novel unfavorable prognostic biomarker ryanodine receptor 1 (RYR1) identified in advanced USC confers their malignant phenotypes, and demonstrated the efficacy of targeting RYR1 by repositioned FDA-approved compounds in USC treatment. Methods: TCGA USC dataset was analyzed to identify top genes that are associated with patient survival or disease stage, and can be targeted by FDA-approved compounds. The top gene RYR1 was selected and the functional role of RYR1 in USC progression was determined by silencing and over-expressing RYR1 in USC cells in vitro and in vivo. The molecular mechanism and signaling networks associated with the functional role of RYR1 in USC progression were determined by reverse phase protein arrays (RPPA), Western blot, and transcriptomic profiling analyses. The efficacy of the repositioned compound dantrolene on USC progression was determined using both in vitro and in vivo models. Results: High expression level of RYR1 in the tumors is associated with advanced stage of the disease. Inhibition of RYR1 suppressed proliferation, migration and enhanced apoptosis through Ca2+-dependent activation of AKT/CREB/PGC-1α and AKT/HK1/2 signaling pathways, which modulate mitochondrial bioenergetics properties, including oxidative phosphorylation, ATP production, mitochondrial membrane potential, ROS production and TCA metabolites, and glycolytic activities in USC cells. Repositioned compound dantrolene suppressed USC progression and survival in mouse models. Conclusions: These findings provided insight into the mechanism by which RYR1 modulates the malignant phenotypes of USC and could aid in the development of dantrolene as a repurposed therapeutic agent for the treatment of USC to improve patient survival. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

35. SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment

Author

Zhu, Ying, primary, Ferri-Borgogno, Sammy, additional, Sheng, Jianting, additional, Yeung, Tsz-Lun, additional, Burks, Jared K., additional, Cappello, Paola, additional, Jazaeri, Amir A., additional, Kim, Jae-Hoon, additional, Han, Gwan Hee, additional, Birrer, Michael J., additional, Mok, Samuel C., additional, and Wong, Stephen T. C., additional

Published
2021
Full Text
View/download PDF

36. Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436

Author

Hu, Wen, primary, Zhang, Li, additional, Ferri-Borgogno, Sammy, additional, Kwan, Suet-Ying, additional, Lewis, Kelsey E., additional, Cun, Han T., additional, Yeung, Tsz-Lun, additional, Soliman, Pamela T., additional, Tarapore, Rohinton S., additional, Allen, Joshua E., additional, Guan, Xinyuan, additional, Lu, Karen H., additional, Mok, Samuel C., additional, and Au-Yeung, Chi-Lam, additional

Published
2021
Full Text
View/download PDF

38. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype

Author

Hu, Wen, primary, Zhang, Li, additional, Ferri-Borgogno, Sammy, additional, Kwan, Suet-Ying, additional, Lewis, Kelsey E., additional, Cun, Han T., additional, Yeung, Tsz-Lun, additional, Soliman, Pamela T., additional, Tarapore, Rohinton S., additional, Allen, Joshua E., additional, Guan, Xinyuan, additional, Lu, Karen H., additional, Mok, Samuel C., additional, and Au-Yeung, Chi-Lam, additional

Published
2020
Full Text
View/download PDF

41. Abstract 1573: Association between TGF-β signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer

Author

Yeung, Tsz-Lun, primary, Locke, George, additional, Lazorchak, Adam, additional, Qin, Guozhong, additional, Yu, Huakui, additional, Qi, Jin, additional, Marelli, Bo, additional, Jenkins, Molly, additional, Rolfe, Alex, additional, Ojalvo, Laureen S., additional, Dussault, Isabelle, additional, and Lan, Yan, additional

Published
2020
Full Text
View/download PDF

42. Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression

Author

Kwan, Suet-Ying, primary, Au-Yeung, Chi-Lam, additional, Yeung, Tsz-Lun, additional, Rynne-Vidal, Angela, additional, Wong, Kwong-Kwok, additional, Risinger, John I., additional, Lin, Hui-Kuan, additional, Schmandt, Rosemarie E., additional, Yates, Melinda S., additional, Mok, Samuel C., additional, and Lu, Karen H., additional

Published
2020
Full Text
View/download PDF

47. Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers

Author

Osmanbeyoglu, Hatice U., primary, Shimizu, Fumiko, additional, Rynne-Vidal, Angela, additional, Alonso-Curbelo, Direna, additional, Chen, Hsuan-An, additional, Wen, Hannah Y., additional, Yeung, Tsz-Lun, additional, Jelinic, Petar, additional, Razavi, Pedram, additional, Lowe, Scott W., additional, Mok, Samuel C., additional, Chiosis, Gabriela, additional, Levine, Douglas A., additional, and Leslie, Christina S., additional

Published
2019
Full Text
View/download PDF

49. An image informatics pipeline for imaging mass cytometry to characterize the immune landscape in pre- and on-treatment immune therapy and its application in recurrent platinium-resistant epithelial ovarian cancer

Author

Zhu, Ying, primary, Yeung, Tsz-Lun, additional, Sheng, Jianting, additional, Hinchcliff, Emily M., additional, Burks, Jared K., additional, Jazaeri, Amir A., additional, Mok, Samuel C., additional, and Wong, Stephen T. C., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results